RAM
IOVA icon

Riggs Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Riggs Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-374
Closed -$1.25K – 938
2025
Q1 		$1.25K Hold
374
– – ﹤0.01% 456
2024
Q4 		$2.68K Hold
374
– – ﹤0.01% 353
2024
Q3 		$3.51K Hold
374
– – ﹤0.01% 320
2024
Q2 		$3K Buy
374
+345
+1,190% +$3.7K ﹤0.01% 338
2024
Q1 		$430 Buy
+29
New +$338 ﹤0.01% 554
2023
Q4 		– Sell
-100
Closed -$455 – 448
2023
Q3 		$455 Buy
+100
New +$653 ﹤0.01% 391

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Riggs Asset Management's IOVA Position: Q2 2025 in Review

Riggs Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 374 shares — an estimated $1.25K sold.

Riggs Asset Management first reported a position in IOVA in Q3 2023 and held it in 6 quarters. The position peaked at $3.51K in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Riggs Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Riggs Asset Management sold 374 Iovance Biotherapeutics shares in Q2 2025, an estimated $1.25K.
  • Riggs Asset Management first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 6 quarters.
  • Riggs Asset Management's Iovance Biotherapeutics position peaked at $3.51K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Riggs Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.